Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proto-Oncogene Proteins c-myc | 1 | 2021 | 7 | 0.740 |
Why?
|
| Plasmablastic Lymphoma | 1 | 2021 | 9 | 0.740 |
Why?
|
| Specimen Handling | 4 | 2019 | 105 | 0.620 |
Why?
|
| Child Mortality | 4 | 2024 | 96 | 0.520 |
Why?
|
| Pneumonia | 3 | 2024 | 131 | 0.510 |
Why?
|
| Cause of Death | 6 | 2024 | 221 | 0.480 |
Why?
|
| Humans | 35 | 2024 | 14537 | 0.460 |
Why?
|
| Skin Neoplasms | 2 | 2008 | 12 | 0.440 |
Why?
|
| Male | 24 | 2022 | 6754 | 0.430 |
Why?
|
| Female | 26 | 2024 | 9103 | 0.420 |
Why?
|
| Middle Aged | 17 | 2022 | 3601 | 0.390 |
Why?
|
| Adult | 19 | 2022 | 5913 | 0.360 |
Why?
|
| Lymphatic Metastasis | 2 | 2008 | 9 | 0.350 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2008 | 2 | 0.350 |
Why?
|
| Aged | 13 | 2022 | 1740 | 0.340 |
Why?
|
| Inclusion Bodies | 1 | 2008 | 1 | 0.310 |
Why?
|
| Fibrosarcoma | 1 | 2008 | 1 | 0.310 |
Why?
|
| Heart Neoplasms | 1 | 2008 | 5 | 0.310 |
Why?
|
| Membrane Proteins | 1 | 2008 | 36 | 0.310 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 32 | 0.300 |
Why?
|
| Gastritis | 1 | 2007 | 3 | 0.290 |
Why?
|
| HIV Infections | 5 | 2021 | 5097 | 0.260 |
Why?
|
| Polyarteritis Nodosa | 1 | 2005 | 2 | 0.260 |
Why?
|
| Periosteum | 1 | 2005 | 2 | 0.260 |
Why?
|
| Esophageal Neoplasms | 2 | 2016 | 26 | 0.250 |
Why?
|
| Autopsy | 5 | 2024 | 140 | 0.250 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2016 | 32 | 0.250 |
Why?
|
| Tuberculosis | 2 | 2007 | 543 | 0.230 |
Why?
|
| Leg | 2 | 2019 | 21 | 0.230 |
Why?
|
| Immunohistochemistry | 2 | 2021 | 26 | 0.220 |
Why?
|
| Standard of Care | 1 | 2024 | 30 | 0.220 |
Why?
|
| South Africa | 16 | 2024 | 7596 | 0.220 |
Why?
|
| Biopsy | 3 | 2014 | 38 | 0.220 |
Why?
|
| Klebsiella pneumoniae | 1 | 2024 | 39 | 0.220 |
Why?
|
| Sarcoma, Kaposi | 5 | 2008 | 53 | 0.210 |
Why?
|
| Prospective Studies | 5 | 2019 | 1160 | 0.210 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2022 | 4 | 0.200 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2014 | 4 | 0.190 |
Why?
|
| In Situ Hybridization | 1 | 2021 | 10 | 0.190 |
Why?
|
| Genes, myc | 1 | 2021 | 6 | 0.190 |
Why?
|
| Stillbirth | 4 | 2024 | 83 | 0.190 |
Why?
|
| Gene Rearrangement | 1 | 2021 | 15 | 0.190 |
Why?
|
| Gene Dosage | 1 | 2021 | 23 | 0.190 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2000 | 187 | 0.180 |
Why?
|
| Infant, Newborn | 5 | 2024 | 1479 | 0.180 |
Why?
|
| Child | 6 | 2024 | 2242 | 0.170 |
Why?
|
| Telepathology | 1 | 2019 | 1 | 0.170 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 146 | 0.170 |
Why?
|
| HIV Seronegativity | 2 | 2018 | 52 | 0.170 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2019 | 11 | 0.170 |
Why?
|
| Infant | 6 | 2024 | 2244 | 0.170 |
Why?
|
| Genotype | 2 | 2018 | 442 | 0.160 |
Why?
|
| Pandemics | 1 | 2022 | 296 | 0.160 |
Why?
|
| Ischemia | 1 | 2019 | 19 | 0.160 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2019 | 27 | 0.160 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2019 | 47 | 0.160 |
Why?
|
| Ventricular Remodeling | 1 | 2019 | 44 | 0.160 |
Why?
|
| Thrombosis | 1 | 2019 | 47 | 0.160 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2019 | 108 | 0.160 |
Why?
|
| Tumor Virus Infections | 1 | 2018 | 3 | 0.160 |
Why?
|
| Child, Preschool | 5 | 2024 | 1748 | 0.160 |
Why?
|
| Alphapapillomavirus | 1 | 2018 | 8 | 0.150 |
Why?
|
| Stroke | 1 | 2019 | 62 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2018 | 115 | 0.150 |
Why?
|
| Neurilemmoma | 1 | 1998 | 1 | 0.150 |
Why?
|
| Abdominal Neoplasms | 1 | 1998 | 3 | 0.150 |
Why?
|
| Bone and Bones | 1 | 1998 | 38 | 0.150 |
Why?
|
| Population Surveillance | 1 | 2019 | 325 | 0.150 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 1997 | 2 | 0.150 |
Why?
|
| Salivary Gland Neoplasms | 1 | 1997 | 4 | 0.150 |
Why?
|
| Aged, 80 and over | 4 | 2014 | 468 | 0.140 |
Why?
|
| Adolescent | 8 | 2021 | 2985 | 0.140 |
Why?
|
| Hypertension | 1 | 2022 | 419 | 0.140 |
Why?
|
| Neoplasms | 3 | 2008 | 147 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2016 | 4 | 0.130 |
Why?
|
| Human papillomavirus 18 | 1 | 2016 | 7 | 0.130 |
Why?
|
| Human papillomavirus 16 | 1 | 2016 | 7 | 0.130 |
Why?
|
| HIV Seropositivity | 1 | 2018 | 265 | 0.130 |
Why?
|
| Dermatomycoses | 1 | 1995 | 1 | 0.130 |
Why?
|
| Beer | 1 | 2015 | 3 | 0.130 |
Why?
|
| Nitrosamines | 1 | 2015 | 3 | 0.130 |
Why?
|
| Cryptococcosis | 1 | 1995 | 17 | 0.130 |
Why?
|
| Marburg Virus Disease | 1 | 2015 | 1 | 0.120 |
Why?
|
| Marburgvirus | 1 | 2015 | 1 | 0.120 |
Why?
|
| Chiroptera | 1 | 2015 | 2 | 0.120 |
Why?
|
| Disease Susceptibility | 1 | 2015 | 46 | 0.120 |
Why?
|
| Pilot Projects | 3 | 2019 | 179 | 0.120 |
Why?
|
| HIV-1 | 4 | 2008 | 1260 | 0.120 |
Why?
|
| Sarcoma | 1 | 2014 | 2 | 0.120 |
Why?
|
| Neoplasm Proteins | 2 | 2008 | 9 | 0.110 |
Why?
|
| Skin | 2 | 2008 | 38 | 0.110 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 1422 | 0.110 |
Why?
|
| Age Factors | 5 | 2019 | 370 | 0.100 |
Why?
|
| Child Health | 2 | 2024 | 77 | 0.090 |
Why?
|
| Pregnancy | 3 | 2024 | 1862 | 0.090 |
Why?
|
| Arenaviridae Infections | 1 | 2009 | 2 | 0.080 |
Why?
|
| Hemorrhagic Fevers, Viral | 1 | 2009 | 2 | 0.080 |
Why?
|
| Arenavirus | 1 | 2009 | 2 | 0.080 |
Why?
|
| Osteoarthropathy, Secondary Hypertrophic | 1 | 2009 | 1 | 0.080 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2009 | 1 | 0.080 |
Why?
|
| Solitary Fibrous Tumor, Pleural | 1 | 2009 | 1 | 0.080 |
Why?
|
| Virus Replication | 2 | 2024 | 88 | 0.080 |
Why?
|
| Hypoglycemia | 1 | 2009 | 4 | 0.080 |
Why?
|
| Perinatal Death | 2 | 2019 | 33 | 0.080 |
Why?
|
| Cross Infection | 1 | 2009 | 52 | 0.080 |
Why?
|
| Keratin-7 | 1 | 2008 | 1 | 0.080 |
Why?
|
| Mucins | 1 | 2008 | 5 | 0.080 |
Why?
|
| Collagen | 1 | 2008 | 23 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2008 | 14 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2008 | 14 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2008 | 25 | 0.080 |
Why?
|
| Spinal Neoplasms | 1 | 2008 | 1 | 0.080 |
Why?
|
| Dendritic Cell Sarcoma, Follicular | 1 | 2008 | 1 | 0.080 |
Why?
|
| Cell Adhesion Molecules | 1 | 2008 | 7 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2008 | 26 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 9 | 0.080 |
Why?
|
| Helicobacter Infections | 1 | 2007 | 8 | 0.070 |
Why?
|
| Cytomegalovirus | 1 | 2007 | 24 | 0.070 |
Why?
|
| Helicobacter pylori | 1 | 2007 | 9 | 0.070 |
Why?
|
| Cytomegalovirus Infections | 1 | 2007 | 23 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2007 | 95 | 0.070 |
Why?
|
| S100 Proteins | 2 | 2015 | 4 | 0.070 |
Why?
|
| Kenya | 1 | 2007 | 183 | 0.070 |
Why?
|
| Fibula | 1 | 2005 | 4 | 0.060 |
Why?
|
| Tibia | 1 | 2005 | 14 | 0.060 |
Why?
|
| Radiography | 1 | 2005 | 80 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2009 | 16 | 0.060 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2007 | 329 | 0.060 |
Why?
|
| Lung | 1 | 2024 | 70 | 0.060 |
Why?
|
| Herpesvirus 8, Human | 1 | 2003 | 14 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2014 | 799 | 0.050 |
Why?
|
| Sepsis | 1 | 2024 | 102 | 0.050 |
Why?
|
| Africa South of the Sahara | 1 | 2024 | 353 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2002 | 63 | 0.050 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2022 | 8 | 0.050 |
Why?
|
| Time Factors | 2 | 2008 | 507 | 0.050 |
Why?
|
| Disease Outbreaks | 2 | 2015 | 111 | 0.050 |
Why?
|
| Length of Stay | 1 | 2022 | 43 | 0.050 |
Why?
|
| Seizures | 1 | 2021 | 20 | 0.050 |
Why?
|
| Respiratory Tract Diseases | 1 | 2021 | 21 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2022 | 90 | 0.050 |
Why?
|
| Gastroenteritis | 1 | 2021 | 22 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 47 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2024 | 293 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2003 | 284 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2009 | 889 | 0.050 |
Why?
|
| Comorbidity | 1 | 2022 | 188 | 0.050 |
Why?
|
| Streptococcus pneumoniae | 1 | 2024 | 336 | 0.050 |
Why?
|
| Diagnosis | 1 | 2019 | 7 | 0.040 |
Why?
|
| Epidemiologic Studies | 1 | 2019 | 13 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 13 | 0.040 |
Why?
|
| Cardiovascular Agents | 1 | 2019 | 11 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 41 | 0.040 |
Why?
|
| Placenta | 1 | 2019 | 44 | 0.040 |
Why?
|
| Gestational Age | 1 | 2019 | 80 | 0.040 |
Why?
|
| Infant Mortality | 1 | 2019 | 97 | 0.040 |
Why?
|
| Critical Illness | 1 | 2019 | 44 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 80 | 0.040 |
Why?
|
| Pre-Eclampsia | 1 | 2019 | 56 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2019 | 107 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 188 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 1998 | 1 | 0.040 |
Why?
|
| Metaplasia | 1 | 1998 | 1 | 0.040 |
Why?
|
| Melanoma-Specific Antigens | 1 | 1998 | 2 | 0.040 |
Why?
|
| Zimbabwe | 1 | 2018 | 120 | 0.040 |
Why?
|
| Prenatal Care | 1 | 2019 | 147 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2008 | 480 | 0.040 |
Why?
|
| Neutrons | 1 | 1997 | 2 | 0.040 |
Why?
|
| Photons | 1 | 1997 | 2 | 0.040 |
Why?
|
| Salivary Glands | 1 | 1997 | 3 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1997 | 9 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 1997 | 4 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 1997 | 25 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 1997 | 50 | 0.040 |
Why?
|
| Linear Models | 1 | 1997 | 83 | 0.040 |
Why?
|
| Survival Rate | 1 | 1997 | 96 | 0.040 |
Why?
|
| Prognosis | 1 | 1997 | 199 | 0.030 |
Why?
|
| Iran | 1 | 2016 | 1 | 0.030 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2016 | 2 | 0.030 |
Why?
|
| China | 1 | 2016 | 21 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2016 | 7 | 0.030 |
Why?
|
| N-Nitrosopyrrolidine | 1 | 2015 | 3 | 0.030 |
Why?
|
| Chemotactic Factors | 1 | 2015 | 6 | 0.030 |
Why?
|
| Carcinogens | 1 | 2015 | 6 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 1995 | 7 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 18 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 1995 | 10 | 0.030 |
Why?
|
| Molecular Docking Simulation | 1 | 2015 | 38 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 1995 | 47 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2019 | 529 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 15 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2014 | 9 | 0.030 |
Why?
|
| Young Adult | 1 | 2019 | 2498 | 0.030 |
Why?
|
| Animals | 1 | 2015 | 1081 | 0.020 |
Why?
|
| Ribavirin | 1 | 2009 | 15 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2009 | 21 | 0.020 |
Why?
|
| C-Peptide | 1 | 2009 | 13 | 0.020 |
Why?
|
| Zambia | 1 | 2009 | 115 | 0.020 |
Why?
|
| Insulin | 1 | 2009 | 73 | 0.020 |
Why?
|
| Contact Tracing | 1 | 2009 | 48 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2009 | 107 | 0.020 |
Why?
|
| Lymphoma, AIDS-Related | 2 | 2000 | 16 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2009 | 111 | 0.020 |
Why?
|
| 12E7 Antigen | 1 | 2008 | 2 | 0.020 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2008 | 4 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2008 | 12 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 37 | 0.020 |
Why?
|
| Prevalence | 2 | 2003 | 1192 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2008 | 563 | 0.020 |
Why?
|
| Age Distribution | 1 | 2003 | 107 | 0.010 |
Why?
|
| Gastric Juice | 1 | 2002 | 6 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2002 | 18 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2002 | 29 | 0.010 |
Why?
|
| Risk Factors | 1 | 2003 | 1475 | 0.010 |
Why?
|
| Sex Factors | 1 | 1995 | 227 | 0.010 |
Why?
|